Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Faculty

Sandy Wong, MD

Associate Professor
Division of Hematology/Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Disclosures

Sandy Wong, MD, has the following relevant financial relationships:
Consultant or advisor for: Catalent Biologics; Dren Biosciences; Sanofi
Research funding from: Bristol Myers Squibb Company; Caleum; Fortis; Genentech; GlaxoSmithKline; Janssen; Patient Discovery

Editors

Megan Whitney, DMD

Medical Education Director, Medscape, LLC 

Disclosures

Megan Whitney, DMD, has no relevant financial relationships.

Tristin Abair, PhD

Senior Medical Writer, Medscape, LLC 

Disclosures

Tristin Abair, PhD, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC

Case Challenges in Newly Diagnosed Multiple Myeloma

Authors: Sandy Wong, MD
CME / ABIM MOC Released: 3/17/2023
Valid for credit through: 3/17/2024, 11:59 PM EST

Start Activity

Credits Available

Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 1.00 ABIM MOC points

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for community-based hematologists/oncologists.

The goal of this activity is for learners to be better able to evaluate patients with newly diagnosed MM and select appropriate therapy in this setting.

Upon completion of this activity, participants will:

Have greater competence related to
- Selecting optimal, individualized first-line therapy in patients with newly diagnosed MM
- Assessing risk status in patients with MM
- Managing adverse events associated with therapy for MM
Demonstrate greater confidence in their ability to
- Select personalized therapy for patients with newly diagnosed MM

Disclosures

Disclosures for additional planners can be found here.

Faculty

Sandy Wong, MD

Associate Professor
Division of Hematology/Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Disclosures

Sandy Wong, MD, has the following relevant financial relationships:
Consultant or advisor for: Catalent Biologics; Dren Biosciences; Sanofi
Research funding from: Bristol Myers Squibb Company; Caleum; Fortis; Genentech; GlaxoSmithKline; Janssen; Patient Discovery

Editors

Megan Whitney, DMD

Medical Education Director, Medscape, LLC 

Disclosures

Megan Whitney, DMD, has no relevant financial relationships.

Tristin Abair, PhD

Senior Medical Writer, Medscape, LLC 

Disclosures

Tristin Abair, PhD, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Case Challenges in Newly Diagnosed Multiple Myeloma

Authors: Sandy Wong, MDFaculty and Disclosures

CME / ABIM MOC Released: 3/17/2023

Valid for credit through: 3/17/2024, 11:59 PM EST

processing....

The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.

CASE 1: PATIENT HISTORY AND PRESENTATION

Bethany is a 64-year-old principal at an elementary school. She has been married for 40 years and has 2 adult children and 4 grandchildren. She is active and healthy, with a history of well-controlled hypertension and hypothyroidism. She had mild atrial fibrillation following COVID-19 infection 3 years ago, which has now improved and does not require medication. She presents to her primary care physician (PCP) with worsening back pain, and a chest x-ray shows multiple lytic lesions. Biopsy confirms the presence of plasma cells and she is referred to a hematologist. Her hematology workup is summarized in Table 1.

Table 1. Bethany's Hematology Workup

	Results
Demographics/patient information	64 years old, female Height: 65 in; weight: 155 lb BMI: 25.8
Personal and family medical history	History of well-controlled hypertension, hypothyroidism History of mild atrial fibrillation, not requiring medication Current medications include lisinopril and levothyroxine No major surgeries No family history of cancer
Physical examination	No lymphadenopathy Tenderness in lower back BP: 125/65 mm Hg; heart rate: 70 bpm ECOG PS: 0
CBC and blood chemistry	WBC count: 9000/mm³ HGB: 10 g/dL Platelets: 175 × 10⁹/L Creatinine: 0.8 mg/dL Albumin: 3.2 g/dL eGFR: 70 mL/min/1.73 m² Calcium: 9.7 mg/dL
Myeloma laboratory evaluations	M-protein: 1.7 g/dL SIFE: IgG kappa IgG: 2000 mg/dL Kappa free light chain: 356 mg/L Beta-2 microglobulin: 5.7 mg/L
FISH	Ordered and waiting on results
PET/CT	Multiple FDG-avid lytic lesions through the axial and appendicular skeleton
Bone marrow biopsy	Bone marrow showed 60% kappa-restricted plasma cells on the core biopsy

Abbreviations: BMI, body mass index; BP, blood pressure; CBC, complete blood count; CT, computed tomography; ECOG, Eastern Cooperative Oncology Group; eGFR, estimated glomerular filtration rate; FDG, fluorodeoxyglucose; FISH, fluorescence in situ hybridization; HGB, hemoglobin; IgG, immunoglobulin G; PET, positron emission tomography; PS, performance status; SIFE, serum immunofixation electrophoresis; WBC, white blood cell.

Page 1 of 14

CME / ABIM MOC Information

Print
Like Tweet

References

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Sandy Wong, MD

Editors

Megan Whitney, DMD

Tristin Abair, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

CME / ABIM MOC

Case Challenges in Newly Diagnosed Multiple Myeloma

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Sandy Wong, MD

Editors

Megan Whitney, DMD

Tristin Abair, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Case Challenges in Newly Diagnosed Multiple Myeloma

CASE 1: PATIENT HISTORY AND PRESENTATION

Table 1. Bethany's Hematology Workup

Megan Whitney, DMD

Megan Whitney, DMD